Tanespimycin: The opportunities and challenges of targeting heat shock protein 90

Expert Opinion on Investigational Drugs

Volumn 18, Issue 6, 2009, Pages 861-868

  Erlichman, Charles ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

Author keywords

17 AAG; Heat shock protein; HSP90; Tanespimycin

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; ANSAMYCIN DERIVATIVE; AT 13387; BENZYLIDENE DERIVATIVE; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; DOCETAXEL; ERLOTINIB; GEFITINIB; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IRINOTECAN; KNK 437; PACLITAXEL; PG 40988; SNX 5422; SORAFENIB; STA 9090; SUNITINIB; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TEMSIROLIMUS; TRASTUZUMAB; TRIPTOLIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; BREAST TUMOR; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; FATIGUE; HUMAN; LIVER TOXICITY; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUTROPENIA; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; SIDE EFFECT; THORAX PAIN; VOMITING;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE;

EID: 67649625171     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902953699     Document Type: Review

References (53)

1. Wandinger SK, Richter K, Buchner J. The Hsp90 chaperone machinery. J Biol Chem 2008;283:18473-18477
2. Pratt WB, Morishima Y, Osawa Y. The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J Biol Chem 2008;283:22885-22889
3. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006;75:271-294 (Pubitemid 44118034)
4. da Rocha Dias S, Friedlos F, Light Y, et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17- demethoxygeldanamycin. Cancer Res 2005;65:10686-10691
5. Grbovic OM, Basso AD, Sawai A, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006;103:57-62
6. Chadli A, Bouhouche I, Sullivan W, et al. Dimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90. Proc Natl Acad Sci USA 2000;97:12524-12529
7. Prodromou C, Panaretou B, Chohan S, et al. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. Embo J 2000;19:4383-4392
8. Available from: htpp://www.picard.ch/downloads/HSP90interactors.pdf.
9. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-410
10. Shamovsky I, Nudler E. New insights into the mechanism of heat shock response activation. Cell Mol Life Sci 2008;65:855-861
11. Xiao H, Perisic O, Lis JT. Cooperative binding of Drosophila heat shock factor to arrays of a conserved 5 bp unit. Cell 1991;64:585-593 (Pubitemid 121002974)
12. Guettouche T, Boellmann F, Lane WS, Voellmy R. Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress. BMC Biochem 2005;6:4 (Pubitemid 40629479)
13. Arya R, Mallik M, Lakhotia SC. Heat shock genes: integrating cell survival and death. J Biosci 2007;32:595-610 (Pubitemid 46708710)
14. Arrigo AP. The cellular 'networking' of mammalian Hsp27 and its functions in the control of protein folding, redox state and apoptosis. Adv Exp Med Biol 2007;594:14-26
15. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007;13:1775-1782
16. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-1893 (Pubitemid 46211366)
17. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino- 17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-1087 (Pubitemid 46202262)
18. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-4161 (Pubitemid 46211321)
19. Nowakowski GS, McCollum AK, Ames MM, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087-6093
20. Solit DB, Egorin M, Valentin G, et al. Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino- 17-demethoxygeldanamycin). ASCO Meeting Abstracts 2004;22:3032
21. Musquire LA, Ramalingam S, Egorin MJ, et al. Phase I and pharmacokinetic (PK) study of 17-allylamino-17 demethoxygeldanamycin (17-AAG) in combination with weekly paclitaxel for advanced solid malignancies. ASCO Meeting Abstracts 2007;25:14028
22. Arlander SJ, Eapen AK, Vroman BT, et al. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 2003;278:52572-52577 (Pubitemid 38035854)
23. Haluska P, Toft DO, Steinmetz SM, et al. A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients. ASCO Meeting Abstracts 2004;22:3058
24. Tse AN, Klimstra DS, Gonen M, et al. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 2008;14:6704-6711
25. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007;25:5410-5417 (Pubitemid 350232217)
26. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-513 (Pubitemid 34411289)
27. Bali P, Pranpat M, Swaby R, et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2. Clin Cancer Res 2005;11:6382-6389
28. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003;63:5126-5135
29. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-3391
30. Mendelson D, Saif MW, Erlichman C, et al. Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors. AACR Meeting Abstracts 2006;47:683
31. Zhang H, Chung D, Yang YC, et al. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 2006;5:1256-1264
32. Eiseman JL, Guo J, Weinbaum B, et al. Evaluation of plasma insulin-like growth factor binding protein 2 (IGFBP-2) as a biomarker for 17-allylamino-17-demethoxygeldanamycin (17-AAG) treatment of adult patients (pts) with advanced solid tumors. ASCO Meeting Abstracts 2005;23:2083 33.
33. Banerji U, Affolter A, Judson I, et al. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 2008;7:737-739
34. Ronnen EA, Kondagunta GV, Ishill N, et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006;24:543-546
35. Heath EI, Hillman DW, Vaishampayan U, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008;14:7940-7946
36. Richardson PG, Chanan-Khan AA, Alsina M, et al. Safety and activity of KOS-953 in patients with relapsed refractory Multiple Myeloma (MM): interim results of a phase 1 trial. ASH Annual Meeting Abstracts. Blood 2005;106:361
37. Price JT, Quinn JM, Sims NA, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005;65:4929-4938
38. Sydor JR, Normant E, Pien CS, et al. Development of 17-allylamino- 17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006;103:17408-17413
39. Wagner AJ, Morgan JA, Chugh R, et al. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. ASCO Meeting Abstracts 2008;26:10503
40. Sequist L, Janne P, Walker J, et al. Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR mutation status. AACR Meeting Abstracts 2007;2007:B79
41. Ramanathan R, Egorin M, Erlichman C, et al. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of 17-dimethylaminoethylamino- 17-demethoxygeldanamycin, (17DMAG, NSC 707545), an inhibitor of heat shock protein 90 (HSP90), in patients with advanced solid tumors: final results. AACR Meeting Abstracts 2007;2007:B212
42. Elfiky A, Saif MW, Beeram M, et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. ASCO Meeting Abstracts 2008;26:2503
43. Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against Xenograft tumor growth, angiogenesis, and metastasis 10.1158/0008-5472.CAN-07-5256. Cancer Res 2008;68:2850-2860
44. Bryson JC, Infante JR, Ramanathan RK, et al. A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422. ASCO Meeting Abstracts 2008;26:14613
45. Thompson N, Lyons J, Chessari G, et al. Hsp90 inhibition by AT13387 modulates growth factor and cytokine stimulated cell signalling in multiple cell lines. AACR Meeting Abstracts 2007;2007:5641
46. McCollum AK, TenEyck CJ, Sauer BM, et al. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res 2006;66:10967-10975
47. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008;14:250-262
48. McCollum AK, TenEyck CJ, Stensgard B, et al. P-glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. Cancer Res 2008;68:7419-7427
49. Chin KV, Tanaka S, Darlington G, et al. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990;265:221-226 (Pubitemid 20032332)
50. Holmes JL, Sharp SY, Hobbs S, Workman P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2008;68:1188-1197 (Pubitemid 351272238)
51. McCollum AK, Lukasiewicz KB, Teneyck CJ, et al. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther 2008;7:3256-3264
52. Westerheide SD, Kawahara TL, Orton K, Morimoto RI. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 2006;281:9616-9622 (Pubitemid 43864680)
53. Koishi M, Yokota S, Mae T, et al. The effects of KNK437, a novel inhibitor of heat shock protein synthesis, on the acquisition of thermotolerance in a murine transplantable tumor in vivo. Clin Cancer Res 2001;7:215-219